Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Julphar
Covington
Deloitte
Express Scripts
Merck
Medtronic
Citi

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FIRMAGON

« Back to Dashboard

Clinical Trials for Firmagon

Trial ID Title Status Sponsor Phase Summary
NCT00451958 A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy Completed Ferring Pharmaceuticals Phase 3 Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.
NCT00801242 Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer Completed Ferring Pharmaceuticals Phase 3 The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.
NCT00833248 Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer Completed Ferring Pharmaceuticals Phase 3 The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, participants were randomly selected (like flipping a coin) to receive either degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide. The treatment was given for three months and the prostate size was measured by ultra sound at the beginning and at the end of the trial. The participants were required to come to the clinic for 5 or 6 visits during the three months.
NCT00884273 Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients Completed Ferring Pharmaceuticals Phase 3 This was a Phase 3b clinical study in prostate cancer patients which aimed to compare the current standard therapy of a gonadotrophin releasing hormone (GnRH) agonist, goserelin (3.6 mg; plus anti-androgen flare protection, bicalutamide), to a novel GnRH antagonist, degarelix (240 mg starting dose/80 mg maintenance dose) with respect to mean percentage reduction in prostate volume. The hypothesis was that degarelix could decrease prostate size at least as effectively as the combination of a GnRH agonist with an anti-androgen for flare protection.
NCT00946920 A Trial of Degarelix in Patients With Prostate Cancer Completed Ferring Pharmaceuticals Phase 3 A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
NCT00947882 A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) Completed Ferring Pharmaceuticals Phase 2 A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
NCT01071915 Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer Completed Ferring Pharmaceuticals Korea, Ltd. Phase 3 This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Firmagon

Condition Name

Condition Name for Firmagon
Intervention Trials
Prostate Cancer 20
Stage IV Prostate Cancer 4
Stage III Prostate Cancer 4
Prostatic Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Firmagon
Intervention Trials
Prostatic Neoplasms 33
Adenocarcinoma 7
Cardiovascular Diseases 2
Ovarian Hyperstimulation Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Firmagon

Trials by Country

Trials by Country for Firmagon
Location Trials
United States 104
Canada 24
Germany 7
Italy 6
United Kingdom 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Firmagon
Location Trials
Colorado 7
Texas 7
California 7
Florida 6
Washington 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Firmagon

Clinical Trial Phase

Clinical Trial Phase for Firmagon
Clinical Trial Phase Trials
Phase 4 3
Phase 3 13
Phase 2 13
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Firmagon
Clinical Trial Phase Trials
Recruiting 13
Completed 12
Active, not recruiting 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Firmagon

Sponsor Name

Sponsor Name for Firmagon
Sponsor Trials
Ferring Pharmaceuticals 22
National Cancer Institute (NCI) 4
Sidney Kimmel Comprehensive Cancer Center 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Firmagon
Sponsor Trials
Other 38
Industry 27
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cipla
Merck
Covington
Federal Trade Commission
US Army
Moodys
Harvard Business School
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.